This protocol describes the first administration of GSK2018682 to humans. The study will
evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending
doses of GSK2018682. The study will also provide preliminary evidence of the potential
therapeutic dose-range by measuring the inhibitory effect of GSK2018682 on total lymphocyte
counts.